Intouch Solutions
JULY 7, 2020
In early March 2020, the violator - a simple badge, or on-page announcement - began to appear on websites. COVID-19 violators are now ubiquitous. Find out why this should matter to pharma marketers. The post COVID-19 and Its Impact on Healthcare Website Design appeared first on Intouch Solutions.
Pharma Marketing Network
JULY 7, 2020
Great digital should be personal. As the Covid-19 environment continues to cause brands to shift more heavily toward digital and increase their non-physical tactics, it is important to remember this. We must work hard to keep these interactions personal. Personalization of content, experiences, and support services is already a mainstay of ecommerce and retail.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
JULY 7, 2020
This week (Monday through Thursday), I’m rerunning some popular posts. Click here to see the original post and comments from February 2020. Pharmacy-related price concessions in Medicare Part D—known as pharmacy DIR fees --have grown faster than most people realize. We estimate that these payments reached $9.1 billion in 2019. This figure indicates that about 18% of total Medicare Part D rebates are now paid by pharmacies, not manufacturers.
Forte Research Systems®
JULY 7, 2020
The COVID-19 pandemic forced an era of research quickly adjusting to continue high-quality research. Most adaptions, however, have positioned research to be more patient centric, streamlined, and remote.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharma in Brief
JULY 7, 2020
The Patented Medicine Prices Review Board ( PMPRB or Board ) has found that a patent can pertain to a medicine based on clinical similarities to the invention—even if the patent does not actually encompass the medicine. Background. This case concerns Canadian Patent No. 2,478,237 (the 237 Patent ), which relates to the use of adapalene to treat dermatological disorders.
Syntegon Technology Pharma Blog
JULY 7, 2020
Expert insights. Personalized for you.
76 
Let's personalize your content